The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1721
ISSUE1721
February 3, 2025
Drugs for Irritable Bowel Syndrome
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Irritable Bowel Syndrome
February 3, 2025 (Issue: 1721)
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D),...more
- BE Lacy et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 2021; 116:17. doi:10.14309/ajg.0000000000001036
- L Chang et al. AGA practice guideline on the pharmacological management of irritable bowel syndrome with constipation. Gastroenterology 2022; 163:118. doi:10.1053/j.gastro.2022.04.016
- A Lembo et al. AGA practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology 2022; 163:137. doi:10.1053/j.gastro.2022.04.017
- AC Ford et al. Irritable bowel syndrome. Lancet 2020; 396:1675. doi:10.1016/s0140-6736(20)31548-8
- SL Eswaran et al. A randomized controlled trial comparing the low FODMAPS diet vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol 2016; 111:1824. doi:10.1038/ajg.2016.434
- S Nybacka et al. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial. Lancet Gastroenterol Hepatol 2024; 9:507. doi:10.1016/s2468-1253(24)00045-1
- F Carbone et al. Diet or medication in primary care patients with IBS: the DOMINO study – a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut 2022; 71:2226. doi:10.1136/gutjnl-2021-325821
- JR Biesiekierski et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106:508. doi:10.1038/ajg.2010.487
- JR Biesiekierski et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145:320. doi:10.1053/j.gastro.2013.04.051
- J Dionne et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol 2018; 113:1290. doi:10.1038/s41395-018-0195-4
- D Nunan et al. Physical activity for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2022; 6:CD011497. doi:10.1002/14651858.cd011497.pub2
- D Schumann et al. Randomised clinical trial: yoga vs a low-FODMAP diet in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2018; 47:203. doi:10.1111/apt.14400
- P Moayyedi et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109:1367. doi:10.1038/ajg.2014.195
- N Alammar et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med 2019; 19:21. doi:10.1186/s12906-018-2409-0
- ZZRM Weerts et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology 2020; 158:123. doi:10.1053/j.gastro.2019.08.026
- P Singh and A Lembo. Emerging role of the gut microbiome in irritable bowel syndrome. Gastroenterol Clin North Am 2021; 50:523. doi:10.1016/j.gtc.2021.03.003
- AC Ford et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2018; 48:1044. doi:10.1111/apt.15001
- GL Su et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology 2020; 159:697. doi:10.1053/j.gastro.2020.05.059
- AF Peery et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology 2024; 166:409. doi:10.1053/j.gastro.2024.01.008
- G Ianiro et al. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2019; 50:240. doi:10.1111/apt.15330
- T Holvoet et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology 2021; 160:145. doi:10.1053/j.gastro.2020.07.013
- P Lahtinen et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther 2020; 51:1321. doi:10.1111/apt.15740
- AC Ford et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol 2019; 114:21. doi:10.1038/s41395-018-0222-5
- CJ Black et al. Efficacy of psychological therapies for irritable bowel syndrome: a systematic review and network meta-analysis. Gut 2020; 69:1441. doi:10.1136/gutjnl-2020-321191
- HA Everitt et al. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut 2019; 68:1613. doi:10.1136/gutjnl-2018-317805
- AC Ford et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 402:1773. doi:10.1016/s0140-6736(23)01523-4
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 5 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- RW Chapman et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013; 108:1508. doi:10.1038/ajg.2013.197
- Lubiprostone (Amitiza) for irritable bowel syndrome with constipation. Med Lett Drugs Ther 2008; 50:53.
- DA Drossman et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29:329. doi:10.1111/j.1365-2036.2008.03881.x
- L Chang et al. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2016; 44:1114. doi:10.1111/apt.13807
- WD Chey et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012; 35:587. doi:10.1111/j.1365-2036.2011.04983.x
- Linaclotide (Linzess) for constipation. Med Lett Drugs Ther 2012; 54:91.
- S Rao et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107:1714. doi:10.1038/ajg.2012.255
- WD Chey et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107:1702. doi:10.1038/ajg.2012.254
- L Chang et al. Efficacy of linaclotide in reducing abdominal symptoms of bloating, discomfort, and pain: a phase 3B trial using a novel abdominal scoring system. Am J Gastroenterol 2021; 116:1929. doi:10.14309/ajg.0000000000001334
- DM Brenner et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol 2018; 113:735. doi:10.1038/s41395-018-0026-7
- Tenapanor (Ibsrela) for irritable bowel syndrome with constipation. Med Lett Drugs Ther 2022; 64:91.
- WD Chey et al. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol 2020; 115:281. doi:10.14309/ajg.0000000000000516
- WD Chey et al. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). Am J Gastroenterol 2021; 116:1294. doi:10.14309/ajg.0000000000001056
- AJ Lembo et al. Abdominal symptom improvement during clinical trials of tenapanor in patients with irritable bowel syndrome with constipation: a post hoc analysis. Am J Gastroenterol 2024; 119:937. doi:10.14309/ajg.0000000000002685
- Rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea. Med Lett Drugs Ther 2015; 57:109.
- M Pimentel et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364:22. doi:10.1056/nejmoa1004409
- A Lembo et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016; 151:1113. doi:10.1053/j.gastro.2016.08.003
- M Camilleri et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2015; 41:438. doi:10.1111/apt.13065
- Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea. Med Lett Drugs Ther 2016; 58:4.
- AJ Lembo et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 2016; 374:242. doi:10.1056/nejmoa1505180
- In brief: Pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder. Med Lett Drugs Ther 2017; 59:70.
- Alosetron (Lotronex) revisited. Med Lett Drugs Ther 2002; 44:67.
- FDA. Lotronex (alosetron hydrochloride) information. September 8, 2023. Available at: https://bit.ly/4a5FEhk. Accessed January 15, 2025.
- R Krause et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007; 102:1709. doi:10.1111/j.1572-0241.2007.01282.x
- K Garsed et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014; 63:1617. doi:10.1136/gutjnl-2013-305989
- D Gunn et al. Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial. Aliment Pharmacol Ther 2023; 57:1258. doi:10.1111/apt.17426
- K Tong et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol 2013; 6:344. doi:10.1177/1756283x13491798
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Irritable Bowel Syndrome
Article code: 1721a
Article code: 1721a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.